Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
Sarepta Therapeutics(SRPT) stock is priced at $17.45, giving the company a market capitalization of 1.83B. It carries a P/E multiple of -5.97.
On 2025-11-11, Sarepta Therapeutics(SRPT) stock traded between a low of $16.90 and a high of $17.48. Shares are currently priced at $17.45, which is +3.3% above the low and -0.2% below the high.
Sarepta Therapeutics(SRPT) shares are trading with a volume of 482.31K, against a daily average of 8M.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
SRPT News
In the past week, Sarepta Therapeutics reported third-quarter 2025 earnings with revenue of US$399.36 million and a net loss of US$179.95 million, alongside ann...
Mizuho upgraded Sarepta (SRPT) to Outperform from Neutral with a price target of $26, up from $19. The firm has greater confidence in the adoption of Elevidys f...
Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Sarepta Therapeutics. The associated price target remains the same with $17.00. Elevate Your...
Analyst ratings
54%
of 26 ratingsMore SRPT News
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its dru...
